{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:21:29Z","timestamp":1792581689947,"version":"4.5.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To evaluate 52-week efficacy and safety of a treat-and-extend regimen of intravitreal aflibercept 2 mg on treatment-naive Type 3 neovascularization lesions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Phase IV, prospective, open-label, single-arm, multicenter trial including patients with untreated Stage I\/II Type 3 neovascularization lesions and baseline best-corrected visual acuity between 78 and 23 Early Treatment Diabetic Retinopathy Study letters. Primary endpoint: mean change in best-corrected visual acuity from baseline at 52 weeks.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Thirty-two eyes from 32 patients were included (mean \u00b1 SD age: 78.2 \u00b1 7.7 years, 68.8% females, baseline best-corrected visual acuity: 57.9 \u00b1 15.4 [Snellen fraction 20\/70]). Best-corrected visual acuity increased by 10.5 \u00b1 15.9 Early Treatment Diabetic Retinopathy Study letters at Week 52 (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0001). The mean foveal and choroidal thickness decreased by 129.1 \u00b1 80.1 <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001) and 64.3 \u00b1 96.5 (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0001), respectively. The proportion of patients with intraretinal\/subretinal fluid decreased from 28 (87.5%) at baseline to 3 (11.5%) at Week 52 (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001). Pigment epithelial detachment and lesion area showed nonsignificant changes over 52 weeks. The mean number of injections was 8.0 \u00b1 2.0. Seven (21.9%) patients experienced treatment-related adverse events and two (6.3%) experienced serious adverse events; one (3.1%) ocular serious adverse event requiring treatment withdrawal, endophthalmitis, and one (3.1%) nonocular spontaneously resolved serious adverse event, palpitations. One (3.1%) patient experienced an APTC ATE: nonfatal stroke not related to trial treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>A treat-and-extend regimen of aflibercept improves visual acuity and retinal edema in eyes with Type 3 neovascularization over 52 weeks with good tolerability.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000002582","type":"journal-article","created":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T03:34:29Z","timestamp":1560569669000},"page":"1234-1244","source":"Crossref","is-referenced-by-count":15,"title":["EFFICACY AND SAFETY OF A TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT IN TREATMENT-NAIVE PATIENTS WITH TYPE 3 NEOVASCULARIZATION"],"prefix":"10.1097","volume":"40","author":[{"given":"Luis","family":"Arias","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Hospital Universitari de Bellvitge, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Cervera","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hospital General de Val\u00e8ncia, Val\u00e8ncia, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume Cresp\u00ed","family":"Vilimelis","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Juan","family":"Escobar","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hospital Dos de Maig, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio G\u00f3mez","family":"Escobar","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Zapata","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hospital Universitari Vall d'Hebron, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the AFLIRAP Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230817","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/00006982-200110000-00003","article-title":"Retinal angiomatous proliferation in age-related macular degeneration","volume":"21","author":"Yannuzzi","year":"2001","journal-title":"Retina"},{"key":"R2-20230817","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00417-006-0367-6","article-title":"Clinicopathological findings of retinal angiomatous proliferation","volume":"245","author":"Shimada","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R4-20230817","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ajo.2014.07.006","article-title":"The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration","volume":"158","author":"Jung","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R5-20230817","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1038\/eye.2010.88","article-title":"Incidence of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation","volume":"24","author":"Campa","year":"2010","journal-title":"Eye (Lond)"},{"key":"R6-20230817","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1111\/aos.12748","article-title":"Fellow-eye neovascularization in unilateral retinal angiomatous proliferation in a Korean population","volume":"94","author":"Chang","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"R7-20230817","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ophtha.2017.08.019","article-title":"Clinicopathologic correlation of anti-vascular endothelial growth factor-treated type 3 neovascularization in age-related macular degeneration","volume":"125","author":"Li","year":"2018","journal-title":"Ophthalmology"},{"key":"R8-20230817","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1097\/IAE.0000000000002198","article-title":"Reduced choriocapillaris flow in eyes with type 3 neovascularization and age-related macular degeneration","volume":"38","author":"Borrelli","year":"2018","journal-title":"Retina"},{"key":"R9-20230817","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00417-007-0705-3","article-title":"Choroidal circulatory disturbances associated with retinal angiomatous proliferation on indocyanine green angiography","volume":"246","author":"Koizumi","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R10-20230817","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1001\/archopht.126.12.1664","article-title":"Clinicopathologic correlation of retinal angiomatous proliferation","volume":"126","author":"Monson","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"R11-20230817","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1755-3768.2011.02265.x","article-title":"Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation","volume":"91","author":"Parodi","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"R12-20230817","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1755-3768.2010.01952.x","article-title":"Intravitreal ranibizumab treatment of retinal angiomatous proliferation","volume":"90","author":"Kramann","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"R13-20230817","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12886-015-0172-2","article-title":"One year results of intravitreal ranibizumab monotherapy for retinal angiomatous proliferation: a comparative analysis based on disease stages","volume":"15","author":"Park","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"R14-20230817","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1097\/IAE.0000000000000225","article-title":"Optical coherence tomography-based ranibizumab monotherapy for retinal angiomatous proliferation in Korean patients","volume":"34","author":"Shin","year":"2014","journal-title":"Retina"},{"key":"R15-20230817","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ajo.2007.05.025","article-title":"Intravitreal bevacizumab for the treatment of retinal angiomatous proliferation","volume":"144","author":"Costagliola","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R16-20230817","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.survophthal.2017.01.008","article-title":"Retinal angiomatous proliferation","volume":"62","author":"Tsai","year":"2017","journal-title":"Surv Ophthalmol"},{"key":"R17-20230817","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrd3700","article-title":"Aflibercept","volume":"11","author":"Stewart","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"R18-20230817","doi-asserted-by":"crossref","first-page":"e0133968","DOI":"10.1371\/journal.pone.0133968","article-title":"Treatment frequency and dosing interval of ranibizumab and aflibercept for neovascular age-related macular degeneration in routine clinical practice in the USA","volume":"10","author":"Ferreira","year":"2015","journal-title":"PLoS One"},{"key":"R19-20230817","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/bjo.2007.134874","article-title":"Predicted biological activity of intravitreal VEGF Trap","volume":"92","author":"Stewart","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R20-20230817","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"R21-20230817","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.ophtha.2011.02.039","article-title":"Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"key":"R22-20230817","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.ophtha.2011.03.020","article-title":"The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing","volume":"118","author":"Heier","year":"2011","journal-title":"Ophthalmology"},{"key":"R23-20230817","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"R24-20230817","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1097\/IAE.0b013e3181bfbd46","article-title":"\u201cTreat and extend\u201d dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization\/retinal angiomatous proliferation","volume":"29","author":"Engelbert","year":"2009","journal-title":"Retina"},{"key":"R25-20230817","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","article-title":"Treat-and-extend regimens with ANTI-VEGF agents in retinal diseases: a literature review and consensus recommendations","volume":"35","author":"Freund","year":"2015","journal-title":"Retina"},{"key":"R26-20230817","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3390\/jcm4071380","article-title":"Long-term visual outcomes for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age-related macular degeneration","volume":"4","author":"Mrejen","year":"2015","journal-title":"J Clin Med"},{"key":"R27-20230817","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/eye.2017.67","article-title":"A systematic review to assess the \u201ctreat-and-extend\u201d dosing regimen for neovascular age-related macular degeneration using ranibizumab","volume":"31","author":"Rufai","year":"2017","journal-title":"Eye (Lond)"},{"key":"R28-20230817","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1097\/IAE.0000000000001104","article-title":"Treat-and-extend regimen with aflibercept for retinal angiomatous proliferation","volume":"36","author":"Matsumoto","year":"2016","journal-title":"Retina Phila Pa"},{"key":"R29-20230817","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.oftal.2016.09.005","article-title":"Treat-and-extend approach with aflibercept: effects on different subtypes of age-related choroidal neovascularisation","volume":"92","author":"Castro-Navarro","year":"2017","journal-title":"Arch Soc Espanola Oftalmol"},{"key":"R30-20230817","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000453281","article-title":"One-year outcomes of the treat-and-extend approach with aflibercept in age-related macular degeneration: effects on typical choroidal neovascularization and retinal angiomatous proliferation","volume":"236","author":"Castro-Navarro","year":"2016","journal-title":"Ophthalmologica"},{"key":"R31-20230817","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"R32-20230817","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/IAE.0b013e3181619c55","article-title":"Review of retinal angiomatous proliferation or type 3 neovascularization","volume":"28","author":"Yannuzzi","year":"2008","journal-title":"Retina"},{"key":"R33-20230817","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1136\/bjophthalmol-2016-309818","article-title":"UK AMD\/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice","volume":"101","author":"Lee","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"R34-20230817","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/aos.13356","article-title":"Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration","volume":"95","author":"Kvannli","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"R35-20230817","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/bjophthalmol-2015-307299","article-title":"Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration","volume":"100","author":"Hatz","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R36-20230817","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00417-014-2835-8","article-title":"Intravitreal aflibercept treatment of retinal angiomatous proliferation: a pilot study and short-term efficacy","volume":"253","author":"Tsaousis","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R37-20230817","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12886-017-0497-0","article-title":"Short-term efficacy of intravitreal aflibercept injections for retinal angiomatous proliferation","volume":"17","author":"Chou","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"R38-20230817","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1089\/jop.2015.0125","article-title":"Factors predictive of visual outcome 1 year after intravitreal aflibercept injection for typical neovascular age-related macular degeneration","volume":"32","author":"Kikushima","year":"2016","journal-title":"J Ocul Pharmacol Ther"},{"key":"R39-20230817","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/bjophthalmol-2015-308074","article-title":"Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study","volume":"100","author":"Kim","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R40-20230817","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ophtha.2015.10.039","article-title":"Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration","volume":"123","author":"Koizumi","year":"2016","journal-title":"Ophthalmology"},{"key":"R41-20230817","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ophtha.2016.10.002","article-title":"Macular atrophy in neovascular age-related macular degeneration with monthly versus treat-and-extend ranibizumab: findings from the TREX-AMD trial","volume":"124","author":"Abdelfattah","year":"2017","journal-title":"Ophthalmology"},{"key":"R42-20230817","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/IAE.0000000000002054","article-title":"MACULAR atrophy incidence in anti-vascular endothelial growth factor-treated neovascular age-related macular degeneration: risk factor evaluation for individualized treatment need of ranibizumab or aflibercept according to an observe-and-plan regimen","volume":"39","author":"Mantel","year":"2018","journal-title":"Retina"},{"key":"R43-20230817","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Fleckenstein","year":"2017","journal-title":"Ophthalmology"},{"key":"R44-20230817","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"key":"R45-20230817","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/eye.2016.208","article-title":"Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents","volume":"31","author":"Gemenetzi","year":"2017","journal-title":"Eye (Lond)"},{"key":"R46-20230817","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/IAE.0000000000000374","article-title":"Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"35","author":"Xu","year":"2015","journal-title":"Retina"},{"key":"R47-20230817","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1097\/IAE.0000000000001457","article-title":"Retinal pigment epithelial atrophy after anti-vascular endothelial growth factor injections for retinal angiomatous proliferation","volume":"37","author":"Hata","year":"2017","journal-title":"Retina"},{"key":"R48-20230817","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13554-012-0003-4","article-title":"Aflibercept: a potent vascular endothelial growth factor antagonist for neovascular age-related macular degeneration and other retinal vascular diseases","volume":"2","author":"Sophie","year":"2012","journal-title":"Biol Ther"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000002582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T01:14:03Z","timestamp":1692234843000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000002582"}},"subtitle":["A 52-Week, Single-Arm, Multicenter Trial"],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000002582","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}